ARTICLE | Clinical News

Nipent pentostatin: Phase II data; marketed to treat hairy cell leukemia

November 12, 2001 8:00 AM UTC

SUPG said data from 40 of 55 low-grade NHL patients in an ongoing U.S. Phase II trial showed that Nipent in combination with Rituxan rituximab from Idec Pharmaceuticals Corp. (IDPH, San Diego, Calif...